Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebipenem pivoxil hydrobromide in cUTI and acute pyelonephritis
NCT06059846Phase 3Completed
- Sponsor
- Spero Therapeutics
- Start
- Dec 2023
- Primary completion
- Jan 2025
- Countries
- 19
01
Overview
A Phase 3 trial of tebipenem in complicated urinary tract infection (cUTI), acute pyelonephritis, sponsored by Spero Therapeutics. Started Dec 2023; status: completed.
02
Drugs
tebipenem
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT06059846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059846.